Bryson Y J, Dillon M, Lovett M, Acuna G, Taylor S, Cherry J D, Johnson B L, Wiesmeier E, Growdon W, Creagh-Kirk T, Keeney R
N Engl J Med. 1983 Apr 21;308(16):916-21. doi: 10.1056/NEJM198304213081602.
We performed a double-blind placebo-controlled trial of oral acyclovir in the treatment of first episodes of genital herpes simplex virus infections in 48 young adults (31 women and 17 men). Subjects were randomized to receive either placebo or acyclovir (200 mg per dose) five times daily for 10 days; they were examined on at least eight visits until healed and at monthly visits thereafter. Acyclovir treatment, as compared with placebo, significantly reduced virus shedding, new lesion formation after 48 hours, and the duration of genital lesions in both men and women. The total duration and severity of clinical symptoms (such as pain, adenopathy, dysuria, and malaise) were significantly reduced by acyclovir in both men and women by the third and fourth day, respectively (P less than or equal to 0.025), as compared with placebo. No toxicity was observed. Recurrence rates have so far been similar in placebo and acyclovir recipients. Oral acyclovir treatment of first-episode genital herpes simplex virus infections is clinically effective, but it does not seem to prevent virus latency or associated recurrent disease.
我们对48名年轻成人（31名女性和17名男性）进行了一项口服阿昔洛韦治疗初发性单纯疱疹病毒生殖器感染的双盲安慰剂对照试验。受试者被随机分为两组，一组接受安慰剂，另一组接受阿昔洛韦（每剂200毫克），每日5次，共10天；在伤口愈合前至少进行8次检查，此后每月检查一次。与安慰剂相比，阿昔洛韦治疗显著减少了病毒排出、48小时后新病灶形成以及男性和女性生殖器病灶的持续时间。与安慰剂相比，阿昔洛韦在第三天和第四天分别显著减轻了男性和女性临床症状（如疼痛、腺病、排尿困难和不适）的总持续时间和严重程度（P≤0.025）。未观察到毒性。到目前为止，安慰剂组和阿昔洛韦组的复发率相似。口服阿昔洛韦治疗初发性单纯疱疹病毒生殖器感染在临床上是有效的，但似乎不能预防病毒潜伏或相关复发性疾病。
